Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT03268876
Active, not recruiting Observational

The INFLUENCE of Cytoreduction on PRO in EOC

NCT03268876 · tracked via the Priya Life Science Norway tracker
Sponsor
Haukeland University Hospital
Phase
Observational
Started
2021-03-03
Last updated
2024-10-09

Condition(s) studied

Epithelial Ovarian Cancer

Study summary

Based on an improved understanding of how the extent of successful cytoreduction is influenced both by inherent tumor biological characteristics as well as the aggressiveness of the surgical approach this project aims to better define the value of cytoreduction and to use the knowledge gained to develop more individualized therapy and follow-up. This will be achieved through a translational biomedical research approach. Due to the research group's traditions clinical phenotyping, biomarker identification, and clinical trials will be the focus.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Epithelial ovarian cancer * Stage \> II * ECOG \< II * Treated with primary surgery followed by chemotherapy * Willing to participate and to sign the informed consent Exclusion Criteria: * \< 18 years old * Borderline and non-epithelial ovarian tumors * Stage \< II * Advanced ovarian cancer submitted to neoadjuvant chemotherapy * ECOG 3-4 * Pregnancy * Severe cardiopulmonary disease * Patients participating in QoL intervention studies

Primary outcome measure(s)

  • Mean Global Health Score — 2 years
    Is there a relationship between QOL score and immunologic profiling in biological samples?

Trial sites (3)

FacilityCityRegionStatus
Haukeland University Hospital Bergen Norway
Sørlandet sykehus HF Kristiansand Norway
Stavanger University Hospital Stavanger Norway

More Haukeland University Hospital trials in Norway

Invest-CTO PCI Trial Active, not recruiting
Robotized Navigation Compared to Conventional Technique in Total Knee Replacement Active, not recruiting
Effectiveness of a Digital Application for Adolescents With Mild to Moderate Anxiety Recruiting
Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families Recruiting
Primary Aldosteronism in Western Norway Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03268876 on ClinicalTrials.gov ↗ ← All trials in Norway